_latest-developments-in-prostate-cancer-updates-from-titan-card-and-the-era-of-personalised-medicine.jpg "Latest developments in prostate cancer: Updates from TITAN, CARD and the era of personalised medicine from parp Video Screenshot Preview")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
⏲ Duration: 9 min 18 sec
✓ Published: 15-Feb-2020
✓ Published: 15-Feb-2020
Description:
Prof Karim Fizazi (Institut Gustave Roussy, Paris, France), Dr Elena Castro (Spanish National Cancer Research Center, Madrid, Spain) and Prof Axel Merseburger (University Hospital Schleswig-Holstein, Lübeck, Germany) discuss the latest updates in prostate cancer from ASCO GU 2020 in San Francisco. nnProf Merseburger describes the latest data from the TITAN trial, in which the time to second progression (PFS2) result was positive, with the occurrence of no new safety signals. He also explains th
Prof Karim Fizazi (Institut Gustave Roussy, Paris, France), Dr Elena Castro (Spanish National Cancer Research Center, Madrid, Spain) and Prof Axel Merseburger (University Hospital Schleswig-Holstein, Lübeck, Germany) discuss the latest updates in prostate cancer from ASCO GU 2020 in San Francisco. nnProf Merseburger describes the latest data from the TITAN trial, in which the time to second progression (PFS2) result was positive, with the occurrence of no new safety signals. He also explains th
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
Related Videos
_the-role-of-parp-inhibition-in-clinical-practice-a-look-inside-the-e-learning.webp "Understand why, where and how PARP inhibitors work in clinical practice, and look into the future of targeting DDR. The e-learning is designed to support you in selecting the appropriate treatment strategy with PARP inhibitors in the appropriate patient population and to provide the best possible patient care.")
⏲ 70 sec ✓ 25-Sep-2019
_metastatic-granulosa-cell-tumours-and-parp-inhibitors.webp "Prof Ray-Coquard speaks with ecancer about the importance of initial diagnosis and molecular analysis in management of granulosa cell type ovarian cancers.nnShe also discusses clinical trials in this indication, including an upcoming presentation at ESMO 2018 on the first randomised trial for patients on weekly paclitaxel. nnProf Ray-Coquard also discusses the use of PARP inhibitors with antiangeogenic factors to treat ovarian cancers.")
_cocooning-isl-video-01-what-is-it-and-how-do-i-do-it.webp "This HSE guidance is for medically vulnerable people who live in their own home and is in place for 2 weeks from March 27th 2020.nnWhat does cocooning mean? nnIt means measures to protect people who are over 70 years of age or those who are extremely medically vulnerable by minimising all interaction between them and others.nnWhat do we mean by extremely medically vulnerable?n1. People aged 70 years or oldernn2. Solid organ transplant recipientsnn3. People with specific cancers:nn- who are under")
_92.webp "Produced by Acme FilmworksnDirected by Michal Sochanhttp://www.acmefilmworks.com")
_comment-parp-inhibitor-olaparib-plus-bevacizumab-in-women-with-ovarian-cancer.webp "Dr Susana Banerjee comments on data, during a press conference at the 2019 ESMO congress, from the PAOLA-1/ENGOT-ov25 trial.nnThis was a phase III randomised trial which looked at the maintenance combined targeted therapy of PARP inhibitor olaparib added to bevacizumab, in patients with and without a BRCA mutation.nnSign up to ecancer for free to receive tailored email alerts for more videos like this.necancer.org/account/register.php")
⏲ 2 min 63 sec ✓ 28-Sep-2019
_erp-parp-webinar-2-10-23.webp "ERP PARP Webinar 2.10.23 from parp")
_latest-developments-in-prostate-cancer-updates-from-titan-card-and-the-era-of-personalised-medicine.webp "Prof Karim Fizazi (Institut Gustave Roussy, Paris, France), Dr Elena Castro (Spanish National Cancer Research Center, Madrid, Spain) and Prof Axel Merseburger (University Hospital Schleswig-Holstein, Lübeck, Germany) discuss the latest updates in prostate cancer from ASCO GU 2020 in San Francisco. nnProf Merseburger describes the latest data from the TITAN trial, in which the time to second progression (PFS2) result was positive, with the occurrence of no new safety signals. He also explains th")
⏲ 9 min 18 sec ✓ 15-Feb-2020
_protein-poly-adp-ribosylation-identification-regulation-and-translation.webp "Speaker:nYonghao Yu, PhDnUniversity of Texas, SouthwesternnnOur understanding of how the biology of various diseases relates to the central dogma that DNA encodes RNA, which encodes protein has been buoyed by rapid technological advances in DNA and RNA sequencing and has led to some of the first advances in personalized medicine. However, characterization of the final and arguably most actionable element of the central dogma, protein, has lagged behind. We are interested in developing mass spect")
⏲ 44 min 93 sec ✓ 24-Sep-2020
_the-role-of-parp-inhibition-in-clinical-practice-a-look-inside-the-e-learning.jpg)
_metastatic-granulosa-cell-tumours-and-parp-inhibitors.jpg)
_cocooning-isl-video-01-what-is-it-and-how-do-i-do-it.jpg)
_92.jpg)
_comment-parp-inhibitor-olaparib-plus-bevacizumab-in-women-with-ovarian-cancer.jpg)
_erp-parp-webinar-2-10-23.jpg)
_protein-poly-adp-ribosylation-identification-regulation-and-translation.jpg)
![[+]](/images/menu.gif){kind=small}